

Table S1. Antihypertensive medications at each timepoint

Variable	Febuxostat group (n=236)	Control group (n=236)
At 6 months		
ACE-I	23 (9.9%)	25 (10.8%)
ARB	130 (56.0%)	142 (61.2%)
Calcium channel blocker	134 (57.8%)	120 (51.7%)
β -blocker	87 (37.5%)	93 (40.1%)
Diuretic	67 (28.9%)	64 (27.6%)
At 12 months		
ACE-I	20 (8.9%)	23 (10.4%)
ARB	128 (57.1%)	134 (60.6%)
Calcium channel blocker	132 (58.9%)	115 (52.0%)
β -blocker	88 (39.3%)	90 (40.7%)
Diuretic	62 (27.7%)	58 (26.2%)
At 24 months		
ACE-I	17 (7.8%)	18 (8.7%)
ARB	119 (54.6%)	128 (62.1%)
Calcium channel blocker	119 (54.6%)	112 (54.4%)
β -blocker	84 (38.5%)	85 (41.3%)
Diuretic	58 (26.6%)	57 (27.7%)


ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker.

Table S2. Baseline characteristics for BP and PR variability assessment

Variable	All (n=420)	Febuxostat group (n=214)	Control group (n=206)	SMD
Age (years)	70.0 [63.0, 77.0]	70.0 [63.0, 76.0]	70.0 [62.0, 77.0]	0.057
Male	340 (81.0%)	171 (79.9%)	169 (82.0%)	0.054
Body mass index (kg/m ²)	24.6 [22.5, 27.1]	24.4 [22.3, 26.8]	24.9 [22.9, 27.4]	0.045
Hypertension	374 (89.0%)	190 (88.8%)	184 (89.4%)	0.017
Diabetes	160 (38.1%)	81 (37.9%)	79 (38.3%)	0.010
Dyslipidemia	253 (60.2%)	131 (61.2%)	122 (59.2%)	0.041
Current smoking	42 (10.0%)	23 (10.7%)	19 (9.2%)	0.051
Prior myocardial infarction	52 (12.4%)	29 (13.6%)	23 (11.2%)	0.073
Prior stroke	24 (5.7%)	14 (6.5%)	10 (4.9%)	0.073
Prior heart failure	69 (16.4%)	38 (17.8%)	31 (15.0%)	0.073
eGFR (mL/min/1.73 m ²)	55.0 [45.5, 66.7]	55.0 [44.8, 65.9]	55.1 [46.3, 66.9]	0.078
Serum uric acid (mg/dL)	7.6 [7.1, 8.2]	7.6 [7.2, 8.2]	7.6 [7.1, 8.3]	0.039
Medications at baseline				
ACE-I	43 (10.2%)	22 (10.3%)	21 (10.2%)	0.003
ARB	241 (57.4%)	120 (56.1%)	121 (58.7%)	0.054
Calcium channel blocker	223 (53.1%)	118 (55.1%)	105 (51.0%)	0.084
β-blocker	166 (39.5%)	81 (37.9%)	85 (41.3%)	0.070
Diuretic	122 (29.0%)	63 (29.4%)	59 (28.6%)	0.018
Statin	207 (49.3%)	104 (48.6%)	103 (50.0%)	0.028

Values are expressed as median [interquartile range] or number (%). A total of 420 of 472 patients had systolic BP measurement ≥ 3 times during the study period and were included into the BP and PR variability assessment. ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BP, blood pressure; eGFR, estimated glomerular filtration rate; PR, pulse rate; SMD, standardized mean difference.

Figure S1. Association of mean systolic BP and SD and CV of systolic BP with serum uric acid levels at 24 months



Solid and dash lines indicate the febxostat and control groups. Mean systolic BP and SD and CV of systolic BP are adjusted by age, sex, and baseline systolic BP, and are expressed with 95% confidence intervals.

BP, blood pressure; CV, coefficient of variation; SD, standard deviation.